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Abstract 28 
Camelid heavy-chain variable domains (VHHs) are the smallest, intact, antigen-29 
binding units to occur in nature. VHHs possess high degrees of solubility and 30 
robustness enabling generation of multivalent constructs with increased avidity – 31 
characteristics that mark their superiority to other antibody fragments and monoclonal 32 
antibodies. Capable of effectively binding to molecular targets inaccessible to classical 33 
immunotherapeutic agents and easily produced in microbial culture, VHHs are 34 
considered promising tools for pharmaceutical biotechnology. With the aim to 35 
demonstrate the perspective and potential of VHHs for the development of 36 
prophylactic and therapeutic drugs to target diseases caused by bacterial and viral 37 
infections, this review article will initially describe the structural features that underlie 38 
the unique properties of VHHs and explain the methods currently used for the 39 
selection and recombinant production of pathogen-specific VHHs, and then thoroughly 40 
summarise the experimental findings of five distinct studies that employed VHHs as 41 
inhibitors of host–pathogen interactions or neutralisers of infectious agents. Past and 42 
recent studies suggest the potential of camelid heavy-chain variable domains as a 43 
novel modality of immunotherapeutic drugs and a promising alternative to monoclonal 44 
antibodies. VHHs demonstrate the ability to interfere with bacterial pathogenesis by 45 
preventing adhesion to host tissue and sequestering disease-causing bacterial toxins. 46 
To protect from viral infections, VHHs may be employed as inhibitors of viral entry by 47 
binding to viral coat proteins or blocking interactions with cell-surface receptors. The 48 
implementation of VHHs as immunotherapeutic agents for infectious diseases is of 49 
considerable potential and set to contribute to public health in the near future. 50 
 51 
Key words: nanobodies, immunotherapy, single-domain antibody, infectious disease 52 
 53 
 54 
Introduction 55 
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Structure and properties of VHHs 56 
The production and secretion of pathogen-specific antibodies by plasma B lymphocytes 57 
forms an integral part of the adaptive immune response to microbial infections in 58 
vertebrates. Immunoglobulin G (IgG) is the most abundant antibody type in serum 59 
and constitutes for about 75 % of circulating antibodies. Due to its great availability, 60 
IgG is used as the principal antibody in immunological research. It is composed of two 61 
identical light chains and two identical heavy chains connected by disulphide bridges 62 
[1,2]. 63 
Apart from conventional IgG glycoproteins with normal antibody assembly, 64 
sera of Camelidae were found to contain a high abundance of IgG subclasses, i.e. IgG2 65 
and IgG3, devoid of light chains. Moreover, these heavy-chain-only antibodies lack the 66 
constant heavy chain 1 domain (CH1) which causes direct connection of their heavy 67 
chain variable domain (VH) to the hinge. The camelid heavy-chain variable domain 68 
exhibits general structural features of a conventional VH, but is unique in its amino 69 
acid sequence, and therefore denoted as VHH [3]. 70 
Equivalent to conventional VHs, VHHs consist of four framework regions (FRs) 71 
separating the three complementarity determining regions (CDRs) (or hypervariable 72 
regions) that are involved in antigen binding. VHHs are fully functional for antigen 73 
binding and their binding affinities are not affected by the absence of light chains. 74 
Moreover, the repertoire of antigen-binding sites is increased due to broadly size-75 
distributed CDRs with diverse amino acid patterns. Particularly, CDR3 of VHHs 76 
distinguishes itself from CDR3 of conventional VHs by higher variability of its amino 77 
acid residues. CDR3 is on average longer and parts of this region that, in conventional 78 
IgG, associate with the light chain variable domain (VL) are available for antigen 79 
binding in VHHs. These features improve antigen recognition and binding strength, 80 
and thus compensate for the absence of the VL, which normally accounts for half of 81 
the antigen-binding surface. Furthermore, the presence of Cys residues in CDR1 and 82 
CDR3 enables the formation of disulphide bridges that stabilise the structure of the 83 
antigen-binding site [4–6]. 84 
Page 3 of 23
URL: http:/mc.manuscriptcentral.com/giri  Email: abot@mannkindcorp.com
International Reviews of Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
VHH domains are the smallest, naturally occurring, antigen-binding units with a 85 
molecular weight of 15 kDa [7]. Their small size allows for rapid penetration of tissues 86 
and enables construction of engineered multivalent formats with higher avidity than 87 
monoclonal antibodies (mAbs) and other antigen-binding units [8]. Moreover, 88 
solubility is notably increased in VHHs due to the presence of hydrophilic amino acid 89 
residues in FR2. Hence, these antibody fragments are resistant to aggregation and 90 
their monomeric nature is preserved in solution [9]. 91 
Amino acid substitutions cause considerable reshaping of the VHH surface [10] 92 
resulting in a large structural diversity of VHH paratopes, e.g. cavity, protruding loop 93 
and flat surface. Thereby, the binding of epitopes inaccessible to mAbs, such as those 94 
located in the active site of enzymes, is enabled [11]. 95 
Their small size, variability, stability, avidity and solubility characteristics 96 
render VHHs promising tools for immunotherapy.   97 
 98 
Selection and production of VHHs 99 
In order to obtain pathogen-specific VHHs for drug development, their generation 100 
must be artificially induced in an experimental host. For this purpose, camelids are 101 
immunised with a particular antigen isolated from the infectious organism. Peripheral 102 
blood (PB) is collected from which PB lymphocytes are prepared by density gradient 103 
centrifugation. The cells are lysed and mRNA is isolated. Extracts of mRNA are used as 104 
templates for cDNA synthesis by reverse transcription polymerase chain reaction (RT-105 
PCR). In a “nested” approach, Ig heavy chains are amplified with gene-specific 106 
primers. Reamplification of VHH genes with specialised primer sets that introduce 107 
restriction endonuclease (RE) recognition sites at the 5’ and 3’ ends of the RT-PCR 108 
products enables precise RE digestion of VHH cDNAs [12] which are then processed 109 
for screening by phage, ribosome or yeast display [13]. For phage display, the most 110 
common of display technologies, digested products are cloned into the bacteriophage 111 
coat protein gene present in phagemid vectors [14]. The resulting recombinant DNA 112 
molecules are transformed into competent bacterial cells for gene expression. 113 
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Bacterial cells are cultured to high density before infected with a helper phage [12], 114 
which provides packaging functions for phagemids, and thus, promotes phage particle 115 
formation plus their secretion into culture medium [15]. Thereby, a library of 116 
phagemid virions, each expressing a different VHH as fusion with their coat protein, is 117 
constructed. In a selection process, i.e. panning, VHH-displaying phage clones are 118 
applied to microtitre wells coated with the specific antigen. Adsorption of phage 119 
particles on the immobilised antigen, due to antigen–antibody interaction, is revealed 120 
by an indirect enzyme-linked immunosorbent assay (ELISA) using horseradish 121 
peroxidase-conjugated secondary antibodies directed against the phage coat protein. 122 
Vector DNA from positively selected clones is then introduced into Escherichia coli for 123 
bacterial production, with yields between 3 and 6 mg L-1 [12]. 124 
For increased cost efficiency, VHH fragments may be alternatively generated in 125 
lower eukaryotic organisms, esp. yeasts, as these are less fastidious and more 126 
productive, with secretion levels above 250 mg L-1. For this purpose, cDNA encoding 127 
the selected VHH is ligated into an episomal yeast expression vector. Cellular entities 128 
of Saccharomyces cerevisiae or Pichia pastoris are transformed with the recombinant 129 
vector and the pathogen-specific VHH is produced by fermentation [16,17].  130 
Subsequently, purified expressed products are subjected to antibody specificity 131 
and affinity testing by ELISA methods [12], in order to assess their suitability for 132 
further in vitro or in vivo studies. 133 
 134 
VHHs directed against bacterial pathogens 135 
Treatment of dental caries 136 
Insufficient oral care, in combination with a high-sugar diet, augments the 137 
development of diverse biofilm communities on tooth surfaces, i.e. the formation of 138 
dental plaque. Acidic conditions and adhesion sites, provided by the dental plaque, 139 
favour the growth of the oral pathogen Streptococcus mutans on tooth surfaces. S. 140 
mutans further decreases pH by the production of acidic compounds from fermentable 141 
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carbohydrates. Thereby, severe damage is caused to tooth enamel resulting in tooth 142 
decay, which is symptomatic of dental caries [18–20].  143 
Adherence of S. mutans to the salivary pellicle is mediated by the cell surface 144 
streptococcal antigen (SA) I/II [21]. Prevention of adhesin–receptor interactions could 145 
therefore assist in the removal of S. mutans from tooth surfaces. In 2006, Krüger et 146 
al. developed an immunotherapeutic approach for the treatment of caries in patients 147 
with hyposalivation that uses llama VHHs targeted against SA I/II.  148 
Krüger et al. (2006) constructed a VHH antibody library from PB lymphocytes 149 
of llamas immunised with disrupted and intact S. mutans HG982. Screening for llama 150 
VHH directed against S. mutans yielded an antibody specific to SA I/II, denoted S36-151 
VHH [20]. Previous studies had shown that coupling of VHH to enzymes enhances 152 
their therapeutic effect [22]. Therefore, by linkage of the selected VHH and Aspergillus 153 
niger-derived glucose oxidase (GOx), a fusion protein (S36-VHH-GOx) was formed to 154 
enhance the salivary peroxidase system (SPS) [20]. When glucose and oxygen are 155 
available, GOx produces hydrogen peroxide (H2O2), which is required by peroxidase to 156 
oxidise the salivary components iodide (I–) and thiocyanate (SCN–) to the antibacterial 157 
compounds hypoiodite (OI–) and hypothyocyanite (OSCN–) [23]. Genes encoding S36-158 
VHH and S36-VHH-GOx were ligated into S. cerevisiae expression vectors and 159 
produced as described previously [16]. ELISAs demonstrated that the fusion of GOx to 160 
S36-VHH had no negative effect on the binding of SA I/II [20]. 161 
Therapeutic effects of these VHHs on cariogenesis were further assessed in 162 
vivo. For this purpose, the clinical situation in patients with hyposalivation was 163 
simulated by a desalivated rat model. In order to establish a basis for cariogenesis, 164 
rats received a diet high in sucrose and were repeatedly infected with S. mutans NG8. 165 
After three weeks, rats were administered with a single dose of either VHH per day. 166 
Both, S36-VHH and S36-VHH-GOx, were found to decrease colonisation with S. 167 
mutans and to exert an anticariogenic effect, however, not to statistically significant 168 
degrees. Furthermore, no additional therapeutic effect of GOx in the S36-VHH-GOx 169 
fusion protein was observed. Its nonappearance was believed to result from heavy 170 
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plaque accumulation, partial inhibition of enzyme activity by the prevailing low pH as 171 
well as the lack of the electron acceptor oxygen within the plaque [20]. 172 
Although postulated, the SPS could not be enhanced. Due to virtual absence of 173 
saliva, the GOx substrate glucose was scarce, which resulted in minimal H2O2 174 
generation. Consequently, the amount of oxidisable substrate, i.e. I– or SCN–, was 175 
limited leading to considerably low antibacterial effects. Krüger et al. (2006) suggest 176 
administering a mixture of S36-VHH-GOx, lactoperoxidase, and I– or SCN–, in case of 177 
hyposalivation, to achieve a bactericidal effect of the SPS. 178 
 179 
Reduction of lipopolysaccharide toxicity 180 
Lipopolysaccharide (LPS), or endotoxin, is a constituent of the outer membranes of 181 
gram-negative bacteria. When released into the blood stream after infection, it causes 182 
an acute inflammatory response with detrimental effects to organs and tissues, a 183 
condition described as sepsis. Sepsis results from the interaction of LPS with high-184 
affinity LPS receptor complexes present on cells of the immune system and in plasma, 185 
which induces the release of interleukin 8 (IL-8) and other inflammatory cytokines 186 
[24–26].  187 
An important cause of sepsis (and meningitis) is the gram-negative pathogen 188 
Neisseria meningitidis [27]. Meningococcal LPS is classified into twelve distinct 189 
immunotypes (L1 to L12) based on structural diversity of the outer core – a result of 190 
phase variation [28,29]. Albeit the heterogeneous structures of meningococcal LPS, its 191 
lipid A moiety and inner-core regions exhibit considerable conservation among gram-192 
negative bacteria [30].  193 
Protection against a variety of gram-negative bacteria could therefore be 194 
provided by immunotherapy targeting these conserved LPS components [31]. 195 
Prerequisites for the efficient use of antibodies in the prevention of sepsis comprise 196 
the recognition of an epitope located in the conserved inner core of the LPS molecule 197 
and the ability to compete with cell surface LPS receptor complexes. El Khattabi et al. 198 
explored the potential of anti-LPS VHHs for sepsis therapy in 2006. 199 
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From PB lymphocytes of llamas, El Khattabi et al. (2006) generated a 200 
nonimmune, i.e. without immunisation of the animal, VHH phage display library. Four 201 
VHH-displaying phages that specifically bound to LPS immunotype L3 from the N. 202 
meningitidis strain H44/76 were selected, and purified anti-LPS VHHs were 203 
subsequently produced. All VHHs were found to immunoprecipitate meningococcal LPS 204 
forms, while some VHHs additionally reacted with LPS of other gram-negative 205 
pathogens (E. coli B4:O111, Salmonella enterica serovar Typhimurium and Bordetella 206 
pertussis). Epit pe mapping was performed to determine the binding sites of the anti-207 
LPS VHHs. It was revealed that one anti-LPS VHH (VHH 5G) bound within the lipid A 208 
and KDO regions of an rfaC mutant strain, while the other three reacted with an LPS-209 
deficient mutant strain (lpxA) for unknown reasons.  210 
The effect of anti-LPS VHH on the binding of meningococcal L3 LPS by LPS 211 
receptors on innate immune cells was investigated and it was demonstrated that L3 212 
LPS–receptor interactions could be efficiently blocked in the presence of VHH 5G. 213 
Furthermore, it was studied whether eff ctor cell response to LPS could be prevented 214 
by VHH 5G. LPS was effectively sequestered by VHH 5G inhibiting the release of 215 
proinflammatory molecules. In addition, LPS depletion due to immunoprecipitation by 216 
anti-LPS VHHs was assessed to be sufficient for the detoxification of solutions 217 
contaminated with LPS [32]. 218 
With VHH 5G, an antibody was isolated that recognises LPS from different 219 
gram-negative bacteria when present in their outer membra es and in a purified, free 220 
form. VHH 5G is able to disturb interactions between LPS and its receptors, disrupt 221 
corresponding signalling pathways that normally generate sepsis-related effector 222 
molecules, and deplete LPS from aqueous solutions with high efficiency. 223 
 224 
 225 
 226 
Prevention of enterotoxigenic E. coli-induced post-weaning diarrhoea  227 
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Enterotoxigenic E. coli (ETEC) strains are causative of human and porcine morbidity 228 
and mortality [33] as these bacteria express heat-labile and heat-stable enterotoxins 229 
that cause ionic imbalance and secretory type diarrhoea in infected subjects [34,35]. 230 
ETEC virulence is determined, inter alia, by F4 fimbriae, which are filamentous protein 231 
appendages that interact with F4-specific receptors (F4Rs) present on the epithelium 232 
of the small intestine, and thereby mediate the intestinal colonisation by ETEC [36]. 233 
Intestinal isolates of ETEC from piglets with post-weaning diarrhoea (PWD) – a cause 234 
of absent maternal immunity [37] – exhibit prevalence of the serological variant F4ac 235 
[38]. In 2005, Harmsen et al. aimed to use monoclonal VHHs, raised against ETEC 236 
F4ac fimbriae, for PWD immunotherapy. 237 
Harmsen et al. (2005) isolated F4ac fimbriae from the F4 positive (F4+) ETEC 238 
strain CVI-1000, which is devoid of F5, F6, F17, F18 and F41 fimbriae, and used these 239 
to immunise a llama and recover its VHH repertoire from PB lymphocytes. Yeast VHH 240 
expression libraries were created whence six clones, directed against the F4 fimbriae 241 
major subunit, were selected. Two clon s did not significantly inhibit bacterial 242 
attachment to jejunal brush borders and displayed cross-reactivity with other F4 243 
variants, whereas four VHHs that specifically recognised the F4ac fimbrial variant 244 
prevented F4+ ETEC attachment. The llama VHH K609 showed the strongest inhibitory 245 
activity and was therefore subjected to further studies. 246 
First, small intestinal segments of F4R positive (F4R+) piglets, i.e. piglets with 247 
brush borders that bound above six ETEC per unit, were perfused with solutions of 248 
ETEC and different concentrations of K609. Net fluid absorption was measured to 249 
determine the effect of VHHs on ETEC-induced fluid loss. Perfusion with K609 at 4 mg 250 
L–1 accounted for maximal reduction of ETEC-induced fluid loss, however, only to 251 
about 30 %. Second, faecal dry matter content was analysed in two groups of weaned 252 
piglets with severe diarrhoea, evoked by the oral challenge with porcine rotavirus 253 
strain RV277 and the ETEC strain CVI-1000. Subjects of the experimental group were 254 
orally administered daily with either low or high doses of K609, while the control 255 
group received no treatment. Faecal dry matter content of the group treated with 256 
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K609 was higher compared to control piglets, but statistical significance of this 257 
difference was merely recorded for piglets administered with high doses. Overall, 258 
reduction of diarrhoea was poor and improvement of piglet mortality was insignificant. 259 
Possible errors that may have contributed to the limited effectivity of K609 260 
immunotherapy have been suggested. These include degradation of K609 by 261 
proteases of the gastrointestinal tract and the expression of adhesion factors, other 262 
than F4 fimbriae, by the ETEC strain CVI-1000. Furthermore, intestinal colonisation of 263 
ETEC expressing other fimbrial types or F4 variants cannot be prevented by K609 264 
alone, owing to its specificity. It is rather suggested to produce a mixture of VHHs 265 
directed against various ETEC adhesion factors, in order to effectively obviate PWD 266 
[39]. 267 
 268 
VHHs directed against viruses 269 
Treatment of human respiratory syncytial virus infection 270 
Human respiratory syncytial virus (RSV) is the main contributor to lower respiratory 271 
tract infection (LRTI) in infants [40]. Patients who encountered RSV-induced 272 
bronchiolitis or pneumonia during infancy are at increased risk of developing asthma 273 
and chronic obstructive pulmonary disease in adulthood [41,42]. RSV specifically 274 
infects the apical membrane of ciliated respiratory epithelial cells [43] and triggers 275 
clinical symptoms of LRTI after a short incubation period [44]. 276 
RSV pathogenesis is promoted by virulence factors, esp. the envelope 277 
glycoproteins G and F, encoded by a linear single-stranded, nonsegmented, negative-278 
sense RNA molecule [45]. The G protein mediates viral attachment to epithelial cell 279 
receptors [46], whereas the F protein induces the fusion of viral and epithelial cell 280 
membrane which enables the entry of the RSV ribonucleoprotein into host cell 281 
cytoplasm [47]. Furthermore, the F protein evokes the fusion of infected cells with 282 
adjacent cells to form multinucleated cells (syncytia) [48].  283 
RSV is classified into two subgroups, i.e. subgroup A (RSV-A) and subgroup B 284 
(RSV-B), based on antigenic variation of the G protein [49]. In contrast, high 285 
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conservation has been identified in the amino acid sequence of the F protein [50]. The 286 
development of therapeutic agents specifically targeting the F protein could therefore 287 
be highly valuable in the inhibition of viral entry. A trivalent VHH, specific to the RSV F 288 
protein, was recently designed and characterised by Detalle et al. (2016) and 289 
subjected to a functional comparison with its monovalent form and the prophylactic 290 
anti-RSV mAb palivizumab [51]. 291 
Llama immune libraries were generated by injection with soluble recombinant F 292 
protein, inactivated RSV-A or a combination of the two. A monovalent VHH specific to 293 
the RSV F protein (Nb017) was identified from the library. Three units of Nb017 were 294 
additionally formatted into a trivalent VHH, denoted ALX-0171, using flexible GS 295 
linkers. Both RSV-neutralising VHHs were readily produced in a P. pastoris strain.  296 
Assessment of the binding to the RSV F protein, by surface plasmon resonance 297 
analysis, revealed that both ALX-0171 and Nb017 bind its pre-fusion conformation, 298 
where the trimeric format exhibited a marked increase in binding affinity. 299 
Furthermore, the effect of trimeric formatting on RSV neutralisation capacity was 300 
determined by microneutralisation assays. The potency of the trivalent ALX-0171 301 
against RSV-A and RSV-B strains was found to be several thousandfold higher than 302 
that of the monovalent Nb017. Moreover, a significant increase in potency, as 303 
compared to palivizumab, was ascertained.  304 
The capabilities of ALX-0171 and palivizumab to completely suppress RSV 305 
replication were compared at equivalent concentrations. ALX-0171 caused complete 306 
blockage of virus replication in 87 % of viruses tested, whereas palivizumab reduced 307 
viral titres by only 18 %. By studying the binding to RSV mutants with alterations in 308 
antigenic site II or IV of the RSV F protein, it was demonstrated that ALX-0171 309 
specifically targets antigenic site II. Furthermore, it was observed that ALX-0171 310 
partially competes with palivizumab for the binding of the RSV F protein which 311 
suggests overlap of their epitopes.  312 
As Detalle et al. (2016) intended to administer ALX-0171 by nebulisation, it 313 
was determined whether the nebulisation process causes aggregation, fragmentation 314 
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or reduced potency of ALX-0171. Higher- and lower-molecular-weight species were 315 
detected at minimum levels, but ALX-0171 potency remained unaffected.  316 
The in vivo efficacy of ALX-0171 against RSV was studied in cotton rats. ALX-317 
0171 was administered at different doses either by nebulisation before or intranasally 318 
after RSV challenge. Viral loads in the nose and lungs were significantly reduced for all 319 
doses of intranasally administered ALX-0171. Delivered prophylactically via 320 
nebulisation, ALX-0171 reduced nasal RSV titres in a dose-dependent matter and in 321 
the lungs it completely blocked RSV replication, even at the lowest dose tested (1 mg 322 
kg-1). ALX-0171 is therefore superior to palivizumab, which had no effect on viral 323 
titres at doses lower than 15 mg kg-1. 324 
ALX-0171 is a potential therapeutic VHH that specifically and efficiently binds 325 
antigenic site II of the RSV F protein. In comparison to Nb017 and palivizumab, ALX-326 
0171 distinguishes itself by increased neutralisation capacity and inhibition efficiency, 327 
which are a result of its trivalency. Moreover, administration by nebulisation enables 328 
direct delivery of ALX-0171 to the site of infection and hence a faster exertion of its 329 
antiviral effect [52]. 330 
In May 2016, positive results for ALX-0171 in Phase I/IIa clinical trials were 331 
reported by the Belgian biopharmaceutical company Ablynx [53]. 332 
 333 
Eradication of poliovirus-induced infantile paralysis (poliomyelitis) 334 
Poliomyelitis, or infantile paralysis, is a highly contagious disease caused by infection 335 
with poliovirus (PV) [54]. Three distinct serotypes, PV1, PV2 and PV3, all of which 336 
cause paralytic disease, have been identified based on differences in their antigenic 337 
determinants [55]. The single-stranded positive sense RNA genome of PV [56] is 338 
enclosed in a non-enveloped capsid composed of 60 monomers of four different 339 
polypeptides, i.e. viral protein 1 (VP1), VP2, VP3 and VP4 [57], that are arranged in 340 
icosahedral symmetry [58]. PV recognises and binds CD155, a transmembrane 341 
glycoprotein of the Ig superfamily [59]. Extracellular domains of CD155 interact with a 342 
conserved narrow surface depression in the PV capsid, termed canyon [60], inducing a 343 
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conformational change of the virion that initiates cell entry and uncoating [61,62]. In 344 
rare cases, PV reaches the central nervous system where it replicates in motor 345 
neurons of the spinal cord and thereby causes muscle paralysis [63]. 346 
Prophylactic treatment by inactivated polio vaccine (IPV) [64] and oral polio 347 
vaccine [65] led to near eradication of poliomyelitis [66]. Other treatment options 348 
such as mAb 35-1f4, which neutralises PV1 by virion cross-linking [67], and the 349 
capsid-binding pyridazinamine analogue R75761 [68] have been developed. In 2010, 350 
Thys et al. isolated and characterised VHHs specific to PV1 and assessed their antiviral 351 
activity in vitro. 352 
By repeated infection of a dromedary with PV1 Sabin strain and isolation of its 353 
VHH repertoire, an immune library was created. Fifteen VHH clones that positively 354 
reacted with PV1 Sabin strain in an ELISA were further analysed. In a standard 355 
neutralisation assay their abilities to block infectivity of PV1 (vaccine and wild-type 356 
strain), PV2 and PV3 were determined. Neutralising activity against PV2 and PV3 was 357 
non-existent, whereas both the vaccine and wild-type strain of PV1 were neutralised 358 
by five VHHs (PVSP6A, PVSS8A, PVSP19B, PVSS21E, and PVSP29F). HeLa cell cultures 359 
were incubated with dilutions of these VHHs and cell viability was monitored, in order 360 
to reveal possible cytotoxic effects. Cytotoxicity was, however, not demonstrated for 361 
any of the tested VHHs. 362 
Antiviral activities of the neutralising VHHs at different concentrations were 363 
assessed by examination of their cytopathic reduction effect in HeLa cells infected with 364 
PV1, and were compared with that of mAb 35-1f4 and R75761. Full protection from a 365 
PV1-induced cytopathic effect was provided by PVSP6A and PVSP29F at a 366 
concentration below that of R75761. Moreover, these VHHs exhibited protective 367 
activities comparable to mAb 35-1f4. Among the VHHs tested, the lowest half maximal 368 
effective concentration (EC50) values were obtained for PVSP6A and PVSP29F.  369 
In order to further define antiviral activities, abilities of the VHHs to reduce 370 
infectious virus yields were investigated in PV1-infected HeLa cells. Certain 371 
concentrations of PVSP6A and PVSP29F completely abolished virus replication. In 372 
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contrast, cells treated with equal concentrations of mAb 35-1f4 showed residual virus 373 
titres.  374 
For the generation of PV1 neutralisation escape mutants, mixtures of PV1 and 375 
VHH were created. Isolation of resistant viruses failed for PVSP6A and PVSP29F due to 376 
complete inhibition of plaque formation. The other three VHHs were unable to 377 
neutralise about 100 plaque forming units (PFU), which was consistent with the 378 
number of PFU expected for a neutralising mAb [69]. 379 
Thys et al. (2010) aimed to isolate a VHH that could inhibit cellular attachment 380 
and cell entry by binding within the canyon region. Recent studies have demonstrated 381 
that all of the PV1-neutralising VHHs recognise epitopes in the canyon region that 382 
overlap with the binding site for CD155 and thereby block ligand–receptor interactions 383 
[70,71]. Furthermore, PV1 n utralisation escape mutants have been found to bear 384 
amino acid substitutions in capsid VPs closely located to the VHH binding sites [72]. 385 
PVSP6A and PVSP29F were the most potent inhibitors of PV1, among the VHHs 386 
tested. Moreover, their efficacies were superior to R75761 and mAb 35-1f4 at 387 
equivalent concentrations. These VHHs could therefore be used to develop advanced 388 
antiviral drugs that prevent or treat PV1-induced poliomyelitis. Additionally, Thys et al. 389 
(2010) plan to adapt their immunisation protocols to generate a VHH with protective 390 
activity against all of the three PV types, with the aim to contribute to worldwide 391 
eradication of poliomyelitis. 392 
 393 
Conclusions 394 
VHH antibody fragments compare to conventional mAbs in their selectivity, antigen 395 
specificity and binding affinity, but excel in terms of their small size, robustness and 396 
increased solubility, which allow for construction of potent multivalent molecules with 397 
high avidity, and thus are advantageous for the development of therapeutic drugs. 398 
VHHs were found to exceed the in vivo efficacies of certain marketed drugs, especially 399 
when assembled into multimeric formats or linked to enzymes. Microbial production of 400 
VHHs is furthermore a feasible alternative to the generation of mAbs by mammalian 401 
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cell culture [73] and the chemical synthesis of immunological agents. Albeit the great 402 
pharmaceutical potential, no VHH-based agents have been approved for therapy thus 403 
far. However, some VHHs, such as ALX-0171, are already in advanced clinical phases. 404 
Besides their application in prevention and treatment of viral and bacterial 405 
infections, VHHs have been used to combat pathologies such as arthritis [74], cancer 406 
[75] and thrombosis [76], to trace antigens and biomarkers for in vivo diagnostic 407 
imaging [77,78], and to protect against lethal scorpion and snake envenoming 408 
[79,80].  409 
Based on their versatile applicability in the biomedical field, VHHs are predicted 410 
as major contributors to the solving of public health problems of the future. 411 
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